IQVIA™ Real-World Insights Bibliography

Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
Author(s): Avraham Karasik (1), Stefanie Lanzinger (2,3), Elise Chia-Hui Tan (4), Daisuke Yabe (5,6,7 8), Dae Jung Kim (9), Wayne H-H Sheu (10), Cheli Melzer-Cohen (1), Reinhard W. Holl (2), Kyoung-Hwa Ha (9), Kamlesh Khunti (11), Francesco Zaccardi (11), Anuradhaa Subramanian (12), Krishnarajah Nirantharakumar (12,13,14), Thomas Nyström (15), Leo Niskanen (16), Majken Linnemann Jensen (17), Fabian Hoti (18), Riho Klement (19), Anouk Déruaz-Luyet (20), Moe H.Kyaw (21), Lisette Koeneman (22), Dorte Vistisen (23, 24) Bendix Carstensen (23), Sigrun Halvorsen (25), Gisle Langslet (26), Soulmaz Fazeli Farsani (20), Elisabetta Patorno (27), Júlio Núñez (28), EMPRISE Europe and Asia Study Group
Affiliations(s): "1 Maccabi Institute for Research and Innovation Center, Tel Aviv University, Tel Aviv, Israel 2 Institute for Epidemiology and Medical Biometry, ZIBMT, Ulm University, Ulm, Germany 3 German Centre for Diabetes Research (DZD), München-Neuherberg, Germany 4 Department of Health Service Administration, China Medical University, Taichung, Taiwan 5 Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Kyoto, Japan 6 Department of Diabetes, Metabolism and Endocrinology/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan 7 Center for Healthcare Information Technology, Tokai National Higher Education and Research System, Nagoya, Japan 8 Preemptive Food Research Center, Gifu University Institute for Advanced Study, Gifu, Japan 9 Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, South Korea 10 Division of Endocrinology and Metabolism, Taipei Veterans General Hospital, Taipei, Taiwan 11 Leicester Real World Evidence Unit, Leicester Diabetes Centre, University of Leicester, Leicester, UK 12 Institute of Applied Health Research, University of Birmingham, Birmingham, UK 13 Midlands Health Data Research UK, Birmingham, UK 14 DEMAND Hub, University of Birmingham, Birmingham, UK 15 Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Sweden 16 Päijät-Häme Joint Authority for Health and Wellbeing, Päijät-Häme Central Hospital, Lahti Finland and University of Eastern Finland, Kuopio, Finland 17 IQVIA Solutions Denmark A/S, Copenhagen, Denmark 18 IQVIA, Espoo, Finland 19 IQVIA, Tartu, Estonia 20 Boehringer Ingelheim International GmbH, Ingelheim, Germany 21 Boehringer Ingelheim International GmbH, US 22 Lilly Deutschland GmbH, Bad Homburg, Germany 23 Steno Diabetes Center Copenhagen, Herlev, Denmark 24 Department of Public Health, University of Copenhagen, Copenhagen, Denmark 25 Department of Cardiology, Oslo University Hospital Ullevål, and University of Oslo, Oslo, Norway 26 Lipid Clinic, Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway 27 Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA 28 Department of Cardiology, Hospital Clínico Universitario de Valencia, INCLIVA, Universidad de Valencia, CIBER Cardiovascular, Valencia, Spain"
Publication(s):  "Diabetes & Metabolism. 2023 Jan; 101418; ISSN 1262-3636 Virtual Conference: American Diabetes Association, 25-29 June 2021 and EASD 27 September -01 October"
Document Type(s): Article,
Countries: Denmark, Finland, Germany, Norway, Spain, Sweden, UK,
Click here for the abstract
C:
Y:
Cardiovascular disease, Diabetes, Drug safety, Drug Utlization Study,
2023
  L:
A:
English
Clinical setting: hospital, Clinical setting: Primary care,
  Add to report
 
 
Empagliflozin is Associated with Lower Risk of Cardiovascular Events and All-Cause Mortality in Routine Care in East Asia: Results from the EMPRISE Study
Author(s): Dae Jung Kim (1), Wayne H-H Sheu (2), Wook-Jin Chung (3), Daisuke Yabe (4-7), Kyoung Hwa Ha (1), Masaomi Nangaku (8), Elise Chia-Hui Tan (9), Koichi Node (10), Atsutaka Yasui (11), Weiyu Lei (12), Sunwoo Lee (13), Laura Saarelainen (14), Anouk Deruaz-Luyet (15), Moe H. Kyaw (16) and Yutaka Seino (4,17), EMPRISE East Asia Study Group
Affiliations(s): "1 Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, South Korea 2 Division of Endocrinology and Metabolism, Taipei Veterans General Hospital, Taipei, Taiwan 3 Department of Cardiovascular Medicine, Gachon University Gil Medical Center, Incheon, South Korea 4 Kansai Electric Power Medical Research Institute, Kobe, Japan 5 Department of Diabetes, Metabolism and Endocrinology/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan 6 Center for Healthcare Information Technology, Tokai National Higher Education and Research System, Nagoya, Japan 7 Division of Metabolism and Molecular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan 8 Division of Nephrology and Endocrinology, The University of Tokyo, Tokyo, Japan 9 National Research Institute of Chinese Medicine, Ministry of Health and Welfare, Taipei, Taiwan, and Institute of Hospital and Healthcare Administration, National Yang-Ming University, Taipei, Taiwan 10 Department of Cardiovascular Medicine, Saga University, Saga, Japan 11 Nippon Boehringer Ingelheim Co. Ltd., Tokyo, Japan 12 Boehringer Ingelheim Taiwan Ltd., Taipei, Taiwan 13 Boehringer Ingelheim Korea Ltd, Seoul, Korea 14 IQVIA, Espoo, Finland 15 Boehringer Ingelheim International GmbH, Ingelheim, Germany 16 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA 17 Kansai Electric Power Hospital, Osaka, Japan "
Publication(s):  "JDI journal Virtual Conference: ACC, May 2021"
Document Type(s): Article,
Countries: Japan, Korea, Taiwan,
Click here for the abstract
C:
Y:
Cardiovascular disease, Diabetes, Drug safety, Drug Utlization Study,
2023
  L:
A:
English
Clinical setting: hospital, Clinical setting: Primary care, Retrospective cohort analysis,
  Add to report
 
 
Hypercholesterolaemia control in Spain: The same situation with different regional realities
Author(s): Juan Pedro-Botet, Núria Plana, José María Mostaza, Juan José Gómez-Doblas, María Rosa Fernández Olmo, Carlos Escobar Cervantes, José Luis Díaz-Díaz, Raquel Campuzano Ruiz, Pedro Valdivielso, Juan Cosín-Sales
Affiliations(s): Unidad de Lípidos y Riesgo Vascular, Hospital del Mar, Universitat Autònoma de Barcelona, Barcelona, España
Publication(s):  Clinica e investigacion en arteriosclerosis: publicacion oficial de la Sociedad Espanola de Arteriosclerosis, S0214-9168(23)00027-X. 27 Apr. 2023, doi:10.1016/j.arteri.2023.04.001
Document Type(s): Abstract,
Countries: Spain,
Click here for the abstract
C:
Y:
Cardiovascular disease,
2023
  L:
A:
Spanish
Clinical setting: Primary care, Public Health, Quality of life, Survey research,
  Add to report
 
 
Real-world clinical practice of pulmonary arterial hypertension in Japan: Insights from a large administrative database
Author(s): Junichi Omura 1, Kazuki Kitahara 1, Masashi Takano 1, Koki Idehara 2, Seok-Won Kim 2 (rwesheorj 2)
Affiliations(s): 1) Medical Affairs Janssen Pharmaceutical K. K. Tokyo Japan 2) RWES/HEOR IQVIA Solutions Japan K. K. Tokyo Japan
Publication(s):  Pulmonary Circulation
Document Type(s): Article,
Countries: Japan,
Click here for the abstract
C:
Y:
Cardiovascular disease,
2023
  L:
A:
English
Database Study, Retrospective cohort analysis,
  Add to report
 
 
Patient and therapeutic profiles of pulmonary hypertension in chronic lung diseases in Japan: a cohort study using a claims database
Author(s): Kazuki Kitahara 1, Junichi Omura 2, Shingo Wada 3, Seok-Won Kim 3 (rwesheorj 3)
Affiliations(s): 1) Medical Affairs, Janssen Pharmaceutical K.K., 3-5-2 Nishikanda, Chiyoda-ku, Tokyo, 101-0065, Japan. kkitahar@its.jnj.com 2) Medical Affairs, Janssen Pharmaceutical K.K., 3-5-2 Nishikanda, Chiyoda-ku, Tokyo, 101-0065, Japan 3) Real World Evidence Solutions, IQVIA Solutions Japan K.K., 4-10-18 Takanawa, Minato-ku, Tokyo, 108-0074, Japan
Publication(s):  Pulmonary Therapy
Document Type(s): Article, Online article,
Countries: Japan,
Click here for the abstract
C:
Y:
Cardiovascular disease, Respiratory disease,
2023
  L:
A:
English
Database Study, Retrospective cohort analysis,
  Add to report
 
 
Empagliflozin cost-effectiveness analysis in Japanese heart failure with mildly reduced and preserved ejection fraction
Author(s): Hiroyuki Tsutsui 1 2, Hiroyuki Sakamaki 3, Shin-Ichi Momomura 4, Yasushi Sakata 5, Yutaro Kotobuki 6, Stephan Linden 7, Koki Idehara 8, Daisuke Nitta 6 (rwesheorj 8)
Affiliations(s): 1) School of Medicine and Graduate School, International University of Health and Welfare, Tokyo, Japan 2) Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan 3) Kanagawa University of Human Services, School of Health Innovation, Kawasaki, Japan 4) Saitama Citizens Medical Centre, Saitama, Japan 5) Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan 6) Medicine Division, Nippon Boehringer Ingelheim Co., Ltd., Shinagawa, Tokyo, Japan 7) Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany 8) Real World Evidence Solutions & HEOR, IQVIA Solutions Japan K.K., Tokyo, Japan
Publication(s):  ESC Heart Failure
Document Type(s): Article, Online article,
Countries: Japan,
Click here for the abstract
C:
Y:
Cardiovascular disease,
2023
  L:
A:
English
Cost analysis,
  Add to report
 
 
Cost-effectiveness of vonoprazan compared with proton pump Inhibitors in patients taking low-dose aspirin for secondary prevention of cardiovascular events in Japan
Author(s): Masanobu Ishii 1, Takashi Kawai 2, Kenichi Tsujita 3*, Ataru Igarashi 4, Manabu Suzuki 5, Hisato Deguchi 5, Jovelle Fernandez 5 (rwesheorj A)
Affiliations(s): 1) Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Japan 2) Department of Gastroenterological Endoscopy, Tokyo Medical University, Japan 3) Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Japan 4) Department of Health Economics and Outcomes Research, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Japan 5) Japan Medical Office, Takeda Pharmaceutical Company Limited, Japan
Publication(s):  Circulation Journal
Document Type(s): Article,
Countries: Japan,
Click here for the abstract
C:
Y:
Cardiovascular disease,
2022
  L:
A:
English
Cost effectiveness,
  Add to report
 
 
Healthcare resource utilization and quality of life in patients with sarcoidosis-associated pulmonary hypertension
Author(s): Allan Lawrie1,2|Neil Hamilton3|Steven Wood2,4|Fernando Exposto5|Ruvimbo Muzwidzwa5|Louise Raiteri5|Amélie Beaudet6|Audrey Muller6|Rafael Sauter6|Nadia Pillai6|David G. Kiel
Affiliations(s): 1National Heart and Lung Institute,Imperial College London, London, UK2Insigneo Institute for In?Silico Medicine,University of Sheffield, Sheffield, UK3Sheffield Pulmonary Vascular DiseaseUnit, Sheffield Teaching Hospitals NHSFoundation Trust, Royal HallamshireHospital, Sheffield, UK4Scientific Computing, Sheffield TeachingHospitals NHS Foundation Trust, RoyalHallamshire Hospital, Sheffield, UK5IQVIA, London, UK6Actelion Pharmaceuticals Ltd.,Allschwil, Switzerland7Department of Infection, Immunity andCardiovascular Disease, University ofSheffield, Sheffield, UK
Publication(s):  Pulmonary Circulation. 2022;12:e12136.wileyonlinelibrary.com/journal/pul2|1of10https://doi.org/10.1002/pul2.12136
Document Type(s): Article,
Countries: Switzerland, UK,
Click here for the abstract
C:
Y:
Cardiovascular disease, Respiratory disease,
2022
  L:
A:
English
Observational study, Retrospective cohort analysis,
  Add to report
 
 
Thrombotic and cardiovascular events and treatment patterns among patients hospitalized with COVID-19 in Japan: an analysis of a nationwide medical claims database
Author(s): Naoki Terasaka 1*, Yukako Matsuo 2, Hirohide Kataoka 2, Yasuhiko Miyata 2, Yoshio Anazawa 2 (rwesheorj A)
Affiliations(s): 1) Medical Department, Bristol Myers Squibb K.K., Tokyo, Japan 2) Medical Department, Bristol Myers Squibb K.K., Tokyo, Japan
Publication(s):  Cardiology and Therapy
Document Type(s): Article,
Countries: Japan,
Click here for the abstract
C:
Y:
Cardiovascular disease, COVID-19,
2022
  L:
A:
English
Database Study,
  Add to report
 
 
Healthcare resource utilization and quality of life in patients with sarcoidosis-associated pulmonary hypertension
Author(s): Allan Lawrie 1 2, Neil Hamilton 3, Steven Wood 2 4, Fernando Exposto 5, Ruvimbo Muzwidzwa 5, Louise Raiteri 5, Amélie Beaudet 6, Audrey Muller 6, Rafael Sauter 6, Nadia Pillai 6, David G Kiely
Affiliations(s): National Heart and Lung Institute, Imperial College London London UK. 2Insigneo Institute for In-Silico Medicine University of Sheffield Sheffield UK. 3Sheffield Pulmonary Vascular Disease Unit Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital Sheffield UK. 4Scientific Computing, Sheffield Teaching Hospitals NHS Foundation Trust Royal Hallamshire Hospital Sheffield UK. 5IQVIA London UK. 6Actelion Pharmaceuticals Ltd. Allschwil Switzerland. 7Department of Infection, Immunity and Cardiovascular Disease University of Sheffield Sheffield UK.
Publication(s):  Pulm Circ. 2022 Oct; 12(4): e12136. Published online 2022 Sep 30. doi: 10.1002/pul2.12136
Document Type(s): Article,
Countries: England,
Click here for the abstract
C:
Y:
Cardiovascular disease,
2022
  L:
A:
English
Observational study, Retrospective cohort analysis,
  Add to report
 
 
 1 of 53 Next Page Last Page